VivoSeq
Musculoskeletal

Ehlers-Danlos Syndrome

6

Pipeline Programs↗

6

Active Trials↗

6

Companies Involved↗

Ehlers-Danlos syndrome is an early-stage landscape with 6 programs across 6 companies. The most active players are Retrophin, Acer Therapeutics Inc., Eli Lilly. 2 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

34/100

Pipeline Velocity

15/100

Mech. Concentration

50/100

Completion Rate

33/100

Attrition Rate

9/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

R

Retrophin

1 program

Phase 2A

Acer Therapeutics Inc.

1 program

Phase 3Eli Lilly logo

Eli Lilly

1 program

Phase 3S

Scilex Pharmaceuticals, Inc.

1 program

ApprovedM

Manhattan Pain Medicine, PLLC

2 programs

PreclinicalA

Aytu BioPharma, Inc.

0 programs

Preclinical

Pipeline

Programs by Phase

Analysis

Trial Status

11

clinical trials

Not yet recruiting3 · 27%
Unknown status2 · 18%
Active, not recruiting2 · 18%
Completed1 · 9%
Recruiting1 · 9%
Suspended1 · 9%
Other1 · 9%

Clinical Trials

Trial Activity

11 trials

Clinical Trial to Compare the Efficacy of Celiprolol to Placebo in Patients With Vascular Ehlers-Danlos Syndrome
Recruiting·AAcer Therapeutics Inc.·Phase 3·NCT05432466·150 enrolled
Local Anesthetic Response in Ehlers-Danlos Syndrome (EDS) and Healthy Volunteers
Active, not recruiting·VVanderbilt University Medical Center·N/A·NCT04036305·230 enrolled
Local Anesthetic Response in Ehlers-Danlos Syndrome (EDS) and Healthy Volunteers
Active, not recruiting·UUniversity of Calgary·Phase 4·NCT05603741·155 enrolled
The Ultrasound-Guided Dextrose Prolotherapy in Ehlers-Danlos Syndrome Patients
Not yet recruiting·TTulane University·Phase 3·NCT05279937·40 enrolled
Regenerative Medicine for Joint Hypermobility and Instability: A Prospective, Open-Label, Single-Arm, Step-Care Clinical Study
Not yet recruiting·MManhattan Pain Medicine, PLLC·Preclinical·NCT07688096·100 enrolled
Prospective Study of Symptoms in People With and Without Joint Hypermobility
Not yet recruiting·Clarkson University·N/A·NCT07657507·100 enrolled
Mind-Body Therapy for Pain in Ehlers-Danlos Syndrome
Completed·NNational Human Genome Research Institute (NHGRI)·Phase 2·NCT00001966·40 enrolled
Investigate Efficacy, Safety, and Pharmacokinetics of Enzastaurin for the Prevention of Arterial Events in Patients With Vascular Ehlers-Danlos Syndrome.
Suspended·AAytu BioPharma, Inc.·Phase 3·NCT05463679·260 enrolled
Oxytocin for Hypermobile Ehlers-Danlos Syndrome
Terminated·—·Phase 1/2·NCT05405257·2 enrolled
Impact of Oxygen Therapy on Fatigue in Patients With Hypermobile-type Ehlers-Danlos Syndrome
Unknown status·HHospital St. Joseph, Marseille, France·Phase 4·NCT04890431·82 enrolled
Riboflavin Corneal Crosslinking for Brittle Cornea Syndrome and Ehlers-Danlos Syndrome Type VI
Unknown status·HHadassah Medical Organization·N/A·NCT01307527·1 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)